Compare Boston Scientific Corporation (BSX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs LYFT Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while LYFT Inc trades at $15.62 (market cap $5.93B). The key difference: Boston Scientific Corporation is far larger — about 11.2× LYFT Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | LYFT | |
|---|---|---|
Market Cap | $66.37B | $5.93B |
Sector | Health | Industrials |
52-Week High | $108.14 | $24.57 |
52-Week Low | $42.63 | $12.65 |
Enterprise Value | $75.94B | $5.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Lyft trades at $15.67, up 0.38% today, with a bullish technical signal and positive cash flow trends. The stock shows attractive valuation metrics with P/E of 2.29 and P/S of 0.99, while recent earnings have been mixed with Q4 2025 beating expectations but Q1 2026 missing. Revenue growth continues with $6.32B in 2025, and the company maintains strong profitability with 43.82% net income margin. Analyst consensus is mixed with 37% buy ratings and $17.86 price target.
Lyft presents a compelling value opportunity with deep valuation discounts and improving fundamentals, though execution risks remain. The company's transition to profitability and strategic expansion into autonomous vehicles provide growth catalysts, but competitive pressures and earnings volatility require careful monitoring. The stock offers 14% upside to consensus target with manageable downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
